@prefix adms: . @prefix dcat: . @prefix dcatap: . @prefix dct: . @prefix foaf: . @prefix healthdcatap: . @prefix rdfs: . @prefix vcard: . @prefix xsd: . a dcat:Dataset ; dcatap:applicableLegislation ; healthdcatap:numberOfUniqueIndividuals "887"^^xsd:nonNegativeInteger ; dct:accessRights ; dct:creator ; dct:description "1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10. This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1 mutated cases, decreasing the cumulative dose of anthracyclines, omitting cranial irradiation and total body irradiation and individualizing asparaginase therapy for all patients. 2. Does a continuous schedule of Asparaginase lead to less allergic reaction/inactivation of Asparaginase than the standard non continuous schedule of Asparaginase? Patients are randomized to receive noncontinuous PEGasparaginase in IA (induction) and intensification of the Medium Risk group (standard arm A) or to receive continuous PEGasparaginase in IA, IB, M and intensification (continuous arm B) with the same cumulative number of doses of PEGasparaginase. 3. Does prophylactic administration of intravenous immunoglobulins reduce the number of infections during the intensive treatment phases? Patients are randomized in the induction and MR treatment group to receive or not receive prophylactic immunoglobulins. 4. Individualize the dose schedule of asparaginase by therapeutic drug monitoring in order to detect silent inactivation of asparaginase, to prevent allergic/anaphylactic reactions, to switch Asparaginase preparation in time and to prevent too high levels with possible toxicity."@en, ""@nl ; dct:identifier ; dct:issued "2026-03-06T10:34:50.036775"^^xsd:dateTime ; dct:modified "2026-04-13T21:30:31.818627"^^xsd:dateTime ; dct:provenance [ a dct:ProvenanceStatement ; rdfs:label "1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10. This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1 mutated cases, decreasing the cumulative dose of anthracyclines, omitting cranial irradiation and total body irradiation and individualizing asparaginase therapy for all patients. 2. Does a continuous schedule of Asparaginase lead to less allergic reaction/inactivation of Asparaginase than the standard non continuous schedule of Asparaginase? Patients are randomized to receive noncontinuous PEGasparaginase in IA (induction) and intensification of the Medium Risk group (standard arm A) or to receive continuous PEGasparaginase in IA, IB, M and intensification (continuous arm B) with the same cumulative number of doses of PEGasparaginase. 3. Does prophylactic administration of intravenous immunoglobulins reduce the number of infections during the intensive treatment phases? Patients are randomized in the induction and MR treatment group to receive or not receive prophylactic immunoglobulins. 4. Individualize the dose schedule of asparaginase by therapeutic drug monitoring in order to detect silent inactivation of asparaginase, to prevent allergic/anaphylactic reactions, to switch Asparaginase preparation in time and to prevent too high levels with possible toxicity."@en, ""@nl ] ; dct:publisher ; dct:spatial ; dct:title "PROTOCOL ALL 11: Treatment study protocol of the Dutch Childhood Oncology Group for Children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia"@en, ""@nl ; adms:versionNotes ""@en, ""@nl ; dcat:contactPoint ; dcat:keyword "Acute Lymfatische Leukemie"@en ; dcat:theme . a vcard:Kind ; vcard:fn "Hester de Groot-Kruseman" ; vcard:hasEmail . a . a dct:RightsStatement . a dct:Location . a foaf:Agent ; dct:identifier ; vcard:hasEmail ; foaf:homepage ; foaf:name "Princess Máxima Center" .